Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Advertisement
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
Researchers identified several risk factors that predicted thrombosis in adults with ALL.
A study described how the implementation of tisa-cel has affected treatment outcomes in B-ALL.
MRD-negative CR status was able to predict long-term survival in newly diagnosed PH+ ALL.
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Efficacy was based on the MRD-negative CR rate at the end of induction.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.